|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRHL3 |
Gene summary for GRHL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRHL3 | Gene ID | 57822 |
| Gene name | grainyhead like transcription factor 3 | |
| Gene Alias | SOM | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q8TE85 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57822 | GRHL3 | LZE24T | Human | Esophagus | ESCC | 6.15e-05 | 2.61e-01 | 0.0596 |
| 57822 | GRHL3 | P4T-E | Human | Esophagus | ESCC | 1.95e-06 | 2.43e-01 | 0.1323 |
| 57822 | GRHL3 | P5T-E | Human | Esophagus | ESCC | 3.50e-02 | 7.97e-02 | 0.1327 |
| 57822 | GRHL3 | P8T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.64e-01 | 0.0889 |
| 57822 | GRHL3 | P9T-E | Human | Esophagus | ESCC | 7.64e-10 | 1.98e-01 | 0.1131 |
| 57822 | GRHL3 | P10T-E | Human | Esophagus | ESCC | 1.09e-11 | 3.06e-01 | 0.116 |
| 57822 | GRHL3 | P12T-E | Human | Esophagus | ESCC | 2.93e-15 | 3.81e-01 | 0.1122 |
| 57822 | GRHL3 | P15T-E | Human | Esophagus | ESCC | 3.64e-04 | 1.41e-01 | 0.1149 |
| 57822 | GRHL3 | P23T-E | Human | Esophagus | ESCC | 3.67e-12 | 5.03e-01 | 0.108 |
| 57822 | GRHL3 | P26T-E | Human | Esophagus | ESCC | 7.31e-14 | 2.80e-01 | 0.1276 |
| 57822 | GRHL3 | P27T-E | Human | Esophagus | ESCC | 7.31e-03 | 1.01e-01 | 0.1055 |
| 57822 | GRHL3 | P28T-E | Human | Esophagus | ESCC | 4.72e-22 | 4.57e-01 | 0.1149 |
| 57822 | GRHL3 | P30T-E | Human | Esophagus | ESCC | 2.42e-07 | 3.38e-01 | 0.137 |
| 57822 | GRHL3 | P31T-E | Human | Esophagus | ESCC | 3.50e-02 | 7.11e-02 | 0.1251 |
| 57822 | GRHL3 | P39T-E | Human | Esophagus | ESCC | 1.35e-23 | 4.95e-01 | 0.0894 |
| 57822 | GRHL3 | P40T-E | Human | Esophagus | ESCC | 1.22e-02 | 1.24e-01 | 0.109 |
| 57822 | GRHL3 | P52T-E | Human | Esophagus | ESCC | 9.44e-07 | 2.27e-01 | 0.1555 |
| 57822 | GRHL3 | P54T-E | Human | Esophagus | ESCC | 1.94e-07 | 3.18e-01 | 0.0975 |
| 57822 | GRHL3 | P62T-E | Human | Esophagus | ESCC | 1.17e-06 | 1.74e-01 | 0.1302 |
| 57822 | GRHL3 | P74T-E | Human | Esophagus | ESCC | 2.19e-02 | 2.59e-01 | 0.1479 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:000184115 | Esophagus | ESCC | neural tube formation | 75/8552 | 102/18723 | 9.68e-09 | 1.95e-07 | 75 |
| GO:000184314 | Esophagus | ESCC | neural tube closure | 66/8552 | 88/18723 | 1.98e-08 | 3.82e-07 | 66 |
| GO:001402014 | Esophagus | ESCC | primary neural tube formation | 69/8552 | 94/18723 | 4.22e-08 | 7.76e-07 | 69 |
| GO:006060614 | Esophagus | ESCC | tube closure | 66/8552 | 89/18723 | 4.24e-08 | 7.76e-07 | 66 |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:00219159 | Esophagus | ESCC | neural tube development | 101/8552 | 152/18723 | 1.78e-07 | 2.79e-06 | 101 |
| GO:00163316 | Esophagus | ESCC | morphogenesis of embryonic epithelium | 98/8552 | 147/18723 | 2.12e-07 | 3.27e-06 | 98 |
| GO:000183814 | Esophagus | ESCC | embryonic epithelial tube formation | 83/8552 | 121/18723 | 2.78e-07 | 4.08e-06 | 83 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:004206027 | Esophagus | ESCC | wound healing | 243/8552 | 422/18723 | 4.62e-07 | 6.25e-06 | 243 |
| GO:003514815 | Esophagus | ESCC | tube formation | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:00721759 | Esophagus | ESCC | epithelial tube formation | 86/8552 | 132/18723 | 4.81e-06 | 5.10e-05 | 86 |
| GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
| GO:00017387 | Esophagus | ESCC | morphogenesis of a polarized epithelium | 63/8552 | 94/18723 | 2.34e-05 | 2.00e-04 | 63 |
| GO:00600714 | Esophagus | ESCC | Wnt signaling pathway, planar cell polarity pathway | 36/8552 | 52/18723 | 5.05e-04 | 2.79e-03 | 36 |
| GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| GRHL3 | TRANS | Cervix | CC | SPRR1B,TGM1,CSTA, etc. | 9.25e-02 |  |
| GRHL3 | TRANS | Esophagus | ADJ | LYPD3,CSTA,PVRL4, etc. | 4.53e-01 |  |
| GRHL3 | TRANS | Esophagus | HGIN | LYPD3,CSTA,PVRL4, etc. | 3.40e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRHL3 | SNV | Missense_Mutation | rs752673677 | c.893N>A | p.Arg298His | p.R298H | Q8TE85 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRHL3 | SNV | Missense_Mutation | novel | c.1450N>C | p.Asn484His | p.N484H | Q8TE85 | protein_coding | tolerated(0.12) | benign(0) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GRHL3 | SNV | Missense_Mutation | c.71N>G | p.Ser24Cys | p.S24C | Q8TE85 | protein_coding | deleterious(0.03) | possibly_damaging(0.62) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| GRHL3 | SNV | Missense_Mutation | c.1088C>T | p.Ser363Leu | p.S363L | Q8TE85 | protein_coding | deleterious(0.02) | benign(0.192) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GRHL3 | SNV | Missense_Mutation | novel | c.1199N>T | p.Cys400Phe | p.C400F | Q8TE85 | protein_coding | deleterious(0.02) | probably_damaging(0.929) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
| GRHL3 | SNV | Missense_Mutation | rs770938921 | c.1225C>T | p.Arg409Cys | p.R409C | Q8TE85 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GRHL3 | SNV | Missense_Mutation | c.694G>C | p.Glu232Gln | p.E232Q | Q8TE85 | protein_coding | tolerated(0.59) | probably_damaging(0.998) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| GRHL3 | SNV | Missense_Mutation | novel | c.196N>A | p.Tyr66Asn | p.Y66N | Q8TE85 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-LL-A5YP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| GRHL3 | insertion | Frame_Shift_Ins | novel | c.969_970insGACG | p.Phe324AspfsTer9 | p.F324Dfs*9 | Q8TE85 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GRHL3 | insertion | Nonsense_Mutation | novel | c.1693_1694insCTTTCTTGCTTTGACCCTCTAAATCTGTTACTTCCTT | p.Gly565AlafsTer5 | p.G565Afs*5 | Q8TE85 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |